Epithelial Ovarian Cancer Clinical Trials in Houston, Texas

4 studies are recruiting for epithelial ovarian cancer in Houston, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

    Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess the safety and efficacy of neoadjuvant carboplatin and mirvetuximab soravtansine in participants with folate receptor alpha (FRα) -expressing advanced-stage serous …

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Houston Methodist Hospital /ID# 274568, Houston, Texas
    Locations
    70 in total
    Run by
    AbbVie

    See if you can join NCT06890338 on ClinicalTrials.gov

  2. A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer

    This is a Phase 1b open-label, multicenter study, evaluating the safety, tolerability, preliminary clinical activity, pharmacokinetics (PK), and pharmacodynamics of azenosertib (ZN-c3) in combination with other drugs.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Site 0103, Houston, Texas
    Locations
    24 in total
    Run by
    K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc

    See if you can join NCT04516447 on ClinicalTrials.gov

  3. A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

    This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and anti- tumor activity of ETX-19477, a novel reversible small molecule inhibitor of PARG.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    MD Anderson Cancer Center, Houston, Texas
    Locations
    14 in total
    Run by
    858 Therapeutics, Inc.

    See if you can join NCT06395519 on ClinicalTrials.gov

  4. Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors

    The investigational drug to be studied in this protocol, BCA101, is a first-in-class compound that targets both EGFR with TGFβ. Based on preclinical data, this bifunctional antibody may exert synergistic activity in patients with EGFR-driven tumors.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    MD Anderson Cancer Center, Houston, Texas
    Locations
    20 in total
    Run by
    Bicara Therapeutics

    See if you can join NCT04429542 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.